Research area: Population Health > Population Allergy

Overview    

Aravax is a clinical-stage biotechnology company focused on developing immunotherapies that are safe, convenient and precisely targeted. The Aravax AVX-201 study aims to reduce symptoms of peanut allergy in children and teenagers across Australia.

PVX108 is designed to be a peanut allergy treatment that retrains the immune system to tolerate peanut allergens. It does not contain peanut proteins, which may put patients at risk of serious side effects such as severe allergic reactions.

PVX108 has been studied in AVX-001 – a First in Human Phase 1 randomised double-blind clinical trial – to evaluate the safety and tolerability of PVX108 administered intradermally in adult participants with peanut allergy. AVX-001-EXT was a follow-up allergy study that demonstrated PVX108 was safe and well tolerated in participants with peanut allergy, including those with asthma.

In early 2023, Murdoch Children’s Research Institute – along with sites in South Australia, New South Wales and Western Australia – began recruiting for the AVX-201 study.

Information for participants

AVX-201 is a double-blind randomised Phase 2 study, which means participants will receive either PVX108 or a placebo but will not know which arm of the peanut allergy trial they are in until the end of the study.

Who can take part?

• Adolescents aged 12-17 years from early-2023
• Children aged 4-11 years from mid-2023
• Physician-diagnosed with IgE mediated peanut allergy

What will you need to do?

• Participants will be involved in the peanut allergy study for around 18–20 months
• Treatment involves 12 PVX108 injections or a placebo, four weeks apart
• Peanut food challenges will take place before and after treatment

Get involved

The Aravax study is being conducted in allergy clinical trial centres across Victoria, South Australia, New South Wales and Western Australia. Participants can be referred to the study by their allergist or families can enquire directly by contacting the Study Coordinator.

Allergists

If your patient is eligible, please complete the patient referral form and we will contact the family to discuss the study further.

Refer a patient

Parents or caregivers

If your child or adolescent may be eligible or you would like to find out more information, please contact our Study Coordinator.

Contact us

Aravax AVX-201 Study
Murdoch Children's Research Institute
The Royal Children's Hospital
50 Flemington Road
Parkville VIC 3052
Australia

Danielle Kallianiotis, Study Coordinator
Phone: show phone number
Email: show email address